EndoChoice Holdings releases Lumos Adaptive Matrix Imaging system

NewsGuard 100/100 Score

EndoChoice Holdings, Inc. (NYSE: GI) announced the release of Lumos, a novel and proprietary imaging software system as part of the Fuse® Full Spectrum Endoscopy® platform. Scientists and engineers at EndoChoice created Lumos based upon Adaptive Matrix Imaging which analyzes and selectively enhances the vascularity, surface texture, and color of abnormal tissue, providing better clarity for physicians. The company is beginning sales and distribution in the European Union, Asia and other select markets this week after receiving the CE Mark. Release in the US and Japanese markets is expected later this year after appropriate regulatory clearances.

"This is an exciting step forward for endoscopists," said Peter Siersema, MD PhD, Professor of Endoscopic Gastrointestinal Oncology at Radboud University Medical Center, Nijmegen, The Netherlands. "The subtle changes in vascular and tissue patterns are important indicators of potentially pre-cancerous polyps that warrant removal."

In a recent unpublished clinical study, physicians found Lumos Adaptive Matrix Imaging facilitated the enhancement of lesions with pit patterns and was useful throughout the entire procedure. EndoChoice has multiple patents pending on this new technology.

Upper and lower endoscopies are performed by doctors using thin, flexible cameras to screen for a wide variety of diseases including cancer of the gastrointestinal tract. The Fuse system is the only flexible endoscopy system to provide a panoramic 330-degree field of view to physicians and clinical data showed a reduction in the number of missed adenomas during colonoscopies. The Fuse gastroscope provides a 245-degree field of view for upper endoscopy procedures. These expanded and wide-angle views are possible because the Fuse colonoscope uses three cameras and two on the gastroscope.

"This innovation is the result of our close collaboration with Fuse customers around the globe," said Mark Gilreath, Founder and CEO of EndoChoice. "Just as Fuse was a groundbreaking advance for physicians and patients, we believe the Lumos Adaptive Matrix Imaging system will raise the bar yet again."

Source:

EndoChoice

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Majority of AI clinical trials report positive outcomes, yet concerns over generalizability persist